We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection

MedXY Editorial Team•Mar 2, 2026•Gastroenterology
ALG-000184Capsid Assembly Modulatorchronic hepatitis B抗病毒疗法

Highlights of the Phase 1 Study

Potent Antiviral Activity

ALG-000184 demonstrated a robust multi-log reduction in both serum HBV DNA (approximately 3-4 log10 IU/mL) and HBV RNA (approximately 0.5-3.0 log10 copies/mL) across all evaluated doses in a 28-day period.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

AHB-137: First-in-Human Study Shows Promising Antiviral Activity and Safety in Chronic Hepatitis B ManagementAHB-137, an antisense oligonucleotide targeting HBV mRNA, demonstrated safety, favorable pharmacokinetics, and rapid HBsAg reduction in healthy volunteers and chronic hepatitis B patients, supporting further clinical development.Aug 17, 2026Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface AntigenThis study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.Jul 14, 2026Functional Anti-preS1 Antibody Responses and Their Role in Viral Control in Chronic Hepatitis BThis review synthesizes evidence on preS1 antigen and anti-preS1 IgG dynamics in chronic hepatitis B, highlighting their correlations with viral replication, liver inflammation, and functional cure, and elucidates the neutralising potentialJun 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation
In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint
Jun 10, 2026
Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood TransplantA real-world study reveals FCN/GCV combination therapy enhances 1-year survival in HHV-6B encephalitis post-CBT, particularly after neutrophil engraftment, compared to monotherapy. Findings underscore the need for tailored antiviral strategApr 24, 2026
Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical ProspectsPreclinical studies demonstrate that the nucleotide analogue bemnifosbuvir effectively suppresses Hepatitis E virus (HEV) replication, showing synergistic potential with ribavirin and a high genetic barrier to resistance.Mar 8, 2026